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AbstrAct
The incidence of acute kidney injury in pregnancy de-
clined significantly over the second half of the 20th cen-
tury; however, it is still associated with major maternal 
and perinatal morbidity and mortality. A set of system-
ic and renal physiological adaptive mechanisms occur 
during a normal gestation that will constrain several 
changes in laboratory parameters of renal function, 
electrolytes, fluid and acid–base balances. The diag-
nosis of acute kidney injury in pregnancy is based on 
the serum creatinine increase. The usual formulas for 
estimating glomerular filtration rate are not validated 
in this population. During the first trimester of gesta-
tion, acute kidney injury develops most often due to 
hyperemesis gravidarum or septic abortion. In the 
third trimester, the differential diagnosis is more chal-
lenging for the obstetrician and the nephrologist and 
comprises some pathologies that are reviewed in this 
article: preeclampsia/HELLP syndrome, acute fatty 
liver of pregnancy and thrombotic microangiopathies.
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cessibility of improved prenatal care and diagnostic tools 
has been extended, and new therapeutics have been devel-
oped. Despite a favorable trend in incidence rates, mater-
nal and perinatal morbidity and mortality remain significant 
problems. 
AdAptive mechAnisms in pregnAncy
Some physiological changes in the urinary tract occur dur-
ing normal pregnancy. There is an increase in kidney size by 
about 1-1.5 cm due to renal vascular and interstitial space 
volume expansion. Over 90% of pregnant women develop 
a physiological hydronephrosis of pregnancy that is charac-
terized by a dilation of the calyces, renal pelvis and ureters 
(2). This anatomical abnormality may be present until the 
16th postpartum week and promotes urinary stasis in the 
ureters, leading to the development of urinary tract infec-
tions. Three distinct mechanisms explain the development 
of this condition: (a) direct action of estrogen and proges-
terone, (b) inhibition of ureteral peristalsis by prostaglandin 
E2 and (c) partial mechanical obstruction by an increased 
uterus (3).
Systemic vascular resistance is reduced in pregnancy due 
to the low resistance of the uteroplacental vascular circuit 
and vasodilation. Possible factors leading to the vasodila-
tion include a reduction in vascular responsiveness to nor-
epinephrine and angiotensin II, increased endothelial pros-
tacyclin production, increased prolactin and progesterone 
levels and increased nitric oxide synthesis by a route in 
which relaxin, produced by the corpus luteum and placenta, 
is implicated (4). The peripheral vasodilation determines a 
fall in blood pressure that can reach 10 mm Hg during the 
first 24 weeks of gestation. The systemic vessel tone reduc-
introduction
Since 1960, the incidence of acute kidney injury (AKI) in 
pregnancy has been reduced significantly, and currently af-
fects 1 per 20,000 pregnancies (1). The legalization of abor-
tion contributed to this decline in most developed countries, 
leading to a reduction in the number of septic abortions – 
the main cause of AKI in recent decades. Moreover, the ac-
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AKi diAgnosis in pregnAncy 
In the literature, there is a high degree of heterogeneity of di-
agnostic definitions of renal diseases in pregnancy (11), and 
therefore there is no validated definition for AKI. The use of 
the RIFLE classification, which focuses on the plasma crea-
tinine percentage change and on the development of oligu-
ria, is not consensual and further studies are necessary to 
demonstrate its usefulness in pregnant women. A creatinine 
level of ≥1 mg/dL or a rapid rise (by definition, in 48 hours) 
of 0.5 mg/dL above baseline should be investigated (12). 
However, the choice of GFR as a marker of renal function 
has advantages in pregnancy allowing the identification of 
an important compromise of renal function even in the pres-
ence of normal serum creatinine (11). 
A standardization of GFR measurement in pregnancy is far 
from being reached. In 2007, 2 prospective studies were 
published to evaluate the accuracy of formulas for estimat-
ing GFR in pregnant women. Smith et al (13) compared the 
Modification of Diet in Renal Disease (MDRD) Study formula 
with inulin and creatinine clearance by 24-hour urine col-
lection. On the other hand, Alper et al (14) compared both 
versions of the MDRD equation, the Cockcroft-Gault equa-
tion and creatinine clearance by 24-hour urine collection, in 
women with preeclampsia. Both concluded that the MDRD 
and Cockcroft-Gault formulas are inaccurate for the assess-
ment of GFR in this specific population because the first 
underestimates the real GFR value, while the second over-
estimates it. Thus, creatinine clearance by 24-hour urine 
collection remains the gold standard method for estimating 
GFR in pregnancy. 
Routine obstetric care also includes proteinuria evalua-
tion, as it is one of the diagnostic criteria for preeclampsia 
that will be discussed below in detail. Usually this assess-
ment is performed by a semiquantitative method from a 
urine sample, but this shows a high rate of false-positive 
and false-negative results. Proteinuria quantification by 
24-hour urine collection is the gold standard; however, 
some limitations are pointed out – for example, sampling 
errors. The use of the urine protein to creatinine ratio in 
the general population has increased because it is an ac-
curate, reproducible and more convenient method for the 
patient. A meta-analysis involving 974 pregnant women 
(15), showed a sensitivity of 90% and specificity of 78% 
comparing this method (cutoff between 0.19 and 0.25) 
and the gold standard (proteinuria >300 mg/24 hours). 
However, its use in pregnancy is controversial, and pub-
lished studies are discordant (16-18). In daily practice, it is 
reasonable to calculate the urine protein to creatinine ratio 
tion triggers compensatory mechanisms such as (a) cardiac 
output increase, (b) plasma volume increase and (c) renin-
angiotensin-aldosterone system activation (5). Regarding 
kidney hemodynamics, there is a renal plasma flow increase 
during pregnancy that can reach up to 85% in the second 
trimester (6). This change results from the cardiac output 
increase and afferent and efferent arteriole vasodilation, 
secondary to action of some humoral factors such as nitric 
oxide and relaxin synthesis or the resistance to aldosterone 
action. After conception, there is an increased glomerular 
filtration rate (GFR) that can reach 40%-65% of baseline 
throughout pregnancy (6, 7), and which subsides in the first 
3 months postpartum. All of these hemodynamic changes 
explain a serum creatinine reduction in pregnant women to 
0.4-0.5 mg/dL.
In normal pregnancy, there is a decline of the plasma os-
molarity (about 10 mOsm/L) and plasma sodium concen-
tration (5 mEq/L on average) due to a lower threshold for 
stimulation of thirst and vasopressin secretion. The mecha-
nisms behind this are not completely understood, but hu-
man chorionic gonadotropin seems to have an important 
role (8). 
Despite the GFR and sodium filtration fraction increase in 
pregnancy, the sodium balance is maintained by the rise 
of its reabsorption within the proximal convoluted tubule 
and in the distal portions of the nephron (under aldoster-
one influence). Taking into account the increase in serum 
aldosterone levels in pregnancy, one would expect a rise in 
potassium excretion. However, this does not occur, due to 
the competitive action of progesterone that connects to the 
mineralocorticoid receptors located in the distal portions of 
the nephron. The serum concentration of chlorine does not 
change with pregnancy. Often there is hypercalciuria in the 
pregnant woman, explained by an increase of the GFR and 
of the calcium gastrointestinal absorption due to a rise in 
1,25-dihydroxyvitamin D3 levels (9).
The GFR increment also causes other physiological changes, 
including an increase of the uric acid clearance, an increase 
of the filtered glucose load and an increase of the glomerular 
filtration of amino acids. Therefore, the GFR increment and 
the increased permeability of glomerular capillaries to albu-
min raise the fractional excretion of albumin (10).
The hormonal change in gestation, particularly the increased 
progesterone levels, causes hyperventilation and mild respi-
ratory alkalosis. A decrease of about 4 mEq/L in bicarbonate 
concentration is common in the pregnant woman. 
All these physiological adaptive mechanisms have clinical 
consequences in laboratory parameters of renal function, 
electrolytes, fluid and acid–base balances that should be 
taken into account when dealing with a pregnant woman.
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for diagnosis of preeclampsia; however, in questionable 
circumstances, 24-hour urine collection is recommended. 
etiology of AKi in pregnAncy
The differential diagnosis of AKI in pregnancy is a clinical 
challenge since we have to consider some pregnancy-as-
sociated specific diseases, but we cannot dismiss all other 
possible AKI causes that may affect women in the reproduc-
tive age group.
Usually, the development of AKI during pregnancy follows 
a bimodal distribution with 2 incidence peaks: one in the 
first trimester, caused by infections (usually involving septic 
abortion), and the other in the third trimester, due to late 
obstetric complications. As in the general population, the 
causes of AKI in pregnant women are divided into 3 groups: 
prerenal, intrarenal and postrenal (Tab. I). The prerenal 
causes are more common in the earlier stage of pregnancy 
due to hyperemesis gravidarum or acute tubular necrosis in 
the context of septic abortion. In the later stages, AKI devel-
opment is more frequent and usually associated with preec-
lampsia, acute fatty liver of pregnancy, hemolytic uremic 
syndrome (HUS) and sepsis (19, 20). The following pregnan-
cy-associated AKI causes will be discussed in more detail: 
(i) preeclampsia, (ii) hemolysis, elevated liver enzymes and 
low platelet count (HELLP) syndrome, (iii) acute fatty liver of 
pregnancy and (iv) thrombotic microangiopathies.
preeclAmpsiA 
Preeclampsia is a syndrome characterized by the onset of 
hypertension and proteinuria after 20 weeks of gestation in a 
previously normotensive woman (21). This condition occurs 
in 3%-8% of pregnancies in the developed countries (22). 
Pathogenesis
The pathogenesis of preeclampsia is not fully understood 
but involves defects in placentation and systemic endothe-
lial activation. 
At the beginning of pregnancy, cytotrophoblast cells of fetal 
origin migrate through the decidua and part of the myome-
trium to invade maternal spiral arteries that become larger 
caliber vessels of low resistance responsible for maintaining 
blood flow to the development of fetus and placenta (23). 
This invasion is regulated by several factors, including the 
cytotrophoblast differentiation from an epithelial to endothe-
lial phenotype (a process called pseudovasculogenesis) (24) 
and the immunological interaction between HLA molecules 
C, E and G and uterine natural killer cells (25, 26).
In preeclamptic women, cytotrophoblast cells do not express 
some adhesion molecules characteristic of endothelial phe-
notype, therefore they invade the decidual portion of spiral 
arteries but cannot penetrate the myometrium. Because of 
this abnormal remodeling, the spiral arteries do not develop 
in large vascular channels, resulting in placental hypoperfu-
sion (27, 28). Placentation requires an extensive angiogenesis 
to establish an appropriate vascular network to supply fetal 
needs. The placenta produces a wide variety of proangio-
genic proteins (vascular endothelial growth factor [VEGF] and 
placental growth factor [PIGF]), and antiangiogenic media-
tors such as soluble fms-like tyrosine kinase 1 (sFlt-1), whose 
balance determines the normal placental development (29). 
sFlt-1 is increased in placenta and serum of preeclamptic 
women, but this excessive release is still not fully understood 
(perhaps triggered by placental ischemia). This protein binds 
to VEGF and PIGF, preventing its interaction with endothe-
lial receptors on the cell surface, inducing endothelial dys-
function (30-32). Another protein released by the placenta, 
soluble endoglin (sEng), also has an antiangiogenic role, but 
acts through a distinct mechanism of sFlt-1 (33). Both trigger 
endothelial dysfunction and severe preeclampsia (34, 35).
The placental ischemia, reperfusion and associated oxida-
tive stress amplify apoptosis by rupture of syncytial archi-
tecture and promote the release into the maternal circulation 
of several components (syncytiotrophoblast membrane 
microparticles and an excess of antiangiogenic factors, such 
TABLE I 

















HELLP = hemolysis, elevated liver enzymes and low platelet 
count.
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as sFlt-1) that stimulate the synthesis of inflammatory cytok-
ines (36-38). This excessive inflammatory response causes 
endothelial dysfunction, increased vascular reactivity and 
coagulopathy that precede the development of symptom-
atic disease (39).
Clinical features
The definition of preeclampsia is variable mainly in the cases 
with preexisting hypertension or proteinuria (11). The most 
widely accepted diagnostic criteria for preeclampsia are 
presented in Table II. Regarding the disease’s severity, it is 
divided into 2 groups: mild and severe. Severe preeclamp-
sia is indicated by more substantial blood pressure eleva-
tions, a greater degree of proteinuria and the presence of 
symptoms associated with target organ involvement (40). In 
recent years, a new concept has emerged depending on the 
time of disease development: early and late preeclampsia 
(41). Early preeclampsia (before the 34th week of gesta-
tion) is often associated with changes in uterine artery Dop-
pler ultrasound results, fetal growth restriction and adverse 
maternal and perinatal outcomes. On the other hand, late 
preeclampsia (after the 34th week of gestation) seems to 
be strongly associated with maternal features (for example, 
body mass index), normal or slightly increased uterine artery 
resistance index (42) and minimal fetal involvement (43).
Usually the clinical manifestations are nonspecific even in 
severe disease. The most reported symptoms are epigastric 
or right upper quadrant pain (40%-90% of patients). Renal 
involvement in preeclampsia is common and results in a de-
creased renal plasma flow and GFR by 30%-40%. However, 
serum creatinine often remains normal or slightly increased 
(1-1.5 mg/dL), except in severe preeclampsia, in which there 
is the development of moderate/severe AKI. Renal tubular 
function is also impaired in preeclampsia, with an early dys-
function of uric acid tubular secretion. Some authors cor-
relate hyperuricemia with renal histological lesions, clinical 
severity and fetal survival (44). The urine sediment is usually 
benign. The histologic lesion associated with preeclampsia 
is glomerular endotheliosis, characterized by swelling and 
vacuolization of endothelial cells, capillary lumen occlusion, 
with no prominent podocyte alterations or thrombi in the 
capillaries and enlarged glomeruli (45). Immunofluorescence 
may reveal fibrin deposits. 
Preeclampsia risk factors and prevention 
At the first prenatal visit, it is possible to identify several fac-
tors that have been proven to increase the risk of preec-
lampsia development (see Tab. III) (24, 46-49). The detection 
of pregnant women at high risk for preeclampsia involves 
tighter monitoring of the pregnancy evolution, and some 
preventive measures may be indicated. Several studies 
show that daily supplementation with magnesium, fish oil, 
vitamin C or E is not effective (25, 50). Calcium supplemen-
tation in high-risk women and in those with a history of low 
calcium diet appears to reduce the risk of preeclampsia (51). 
A meta-analysis published by the Perinatal Antiplatelet Re-
view of International Studies (PARIS) group demonstrated 
a moderate but consistent reduction in the relative risk of 
preeclampsia with aspirin use (52, 53).
Maternal and perinatal outcomes
The maternal and perinatal outcomes in preeclampsia de-
pend on gestational age at onset, disease severity, type of 
care provided to the pregnant woman and presence of other 
maternal comorbid conditions. Generally, the prognosis is 
favorable for women with mild preeclampsia. Severe preec-
lampsia is associated with maternal, fetal or neonatal com-
plications. The most frequent maternal complications are 
disseminated coagulopathy / HELLP syndrome (10%-20%), 
pulmonary edema (2%-5%), AKI (1%-5%) and placental 
abruption (1%-4%) (21, 54, 55). Long-term epidemiologic 
studies point to an increased risk of cardiovascular disease 
TABLE II 
DIAGNOSTIC CRITERIA FOR PREECLAMPSIA
Preeclampsia
Blood pressure: systolic ≥140 mm Hg or diastolic ≥90 
mm Hg, after 20 weeks of gestation in a previously nor-
motensive woman
AND
Proteinuria: ≥300 mg in a 24-hour urine collection
Severe preeclampsia
Blood pressure: systolic ≥160 mm Hg or diastolic ≥110 
mm Hg, on 2 occasions at least 6 hours apart
Proteinuria: ≥5 g in a 24-hour urine collection
Symptoms associated with target organ involvement:
  Cerebral and visual disturbances
  Pulmonary edema
  Epigastric or right upper quadrant pain
  Impaired liver function
  Thrombocytopenia
  Oliguria
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(chronic hypertension, ischemic heart disease and stroke) 
in severe preeclamptic women (56-58). The fetal/neonatal 
complications that may occur in severe preeclampsia are 
fetal growth restriction (10%-25%), neurologic damage due 
to hypoxia (<1%) and perinatal death (1.2%) (54).
hellp syndrome 
Traditionally, the HELLP syndrome was considered to be a 
variant of preeclampsia, but it is, in fact, a distinct disease, 
since 20% of pregnant women with HELLP syndrome do 
not have a history of hypertension or proteinuria (59, 60). 
This obstetric entity affects 1-2 women per 1,000 pregnan-
cies (61), and its pathogenesis is not fully known. Similar 
preeclampsia mechanisms have been proposed particu-
larly, the decline of proangiogenic mediators (PIGF) and the 
increase of antiangiogenic factors (sFlt-1 and sEng) (62).
HELLP syndrome occurs typically in the third trimester, but 
may be diagnosed in the second trimester or postpartum 
period (63). The clinical features are variable. Symptoms are 
mostly epigastric / right upper quadrant pain, nausea, vom-
iting and headache, but may manifest by its complications: 
disseminated intravascular coagulation, placental abrup-
tion, AKI (7%-36%), pulmonary edema, hepatic subcapsu-
lar hematoma and retinal detachment (25, 64, 65).
The diagnosis of HELLP syndrome is based on the follow-
ing laboratory criteria (64): (a) microangiopathic hemolytic 
anemia: schistocytes in blood smear, serum bilirubin ≥1.2 
mg/dL, lactate dehydrogenase >600 U/L; (b) increased liver 
transaminases (aspartate aminotransferase >70 U/L) and (c) 
platelet count < 100 x 103 cells/mm3. 
Maternal outcome in HELLP syndrome is favorable, often 
with analytic change normalization up to the sixth day after 
delivery. However, recovery may be delayed in more severe 
disease, including if AKI develops during pregnancy. Ap-
proximately 10%-46% of pregnant women with AKI associ-
ated with HELLP syndrome need dialysis in the acute phase 
(66, 67), but even these cases typically show a complete 
recovery of kidney function (66, 68). The most recent pub-
lished studies refer maternal mortality of around 1% (63). 
The perinatal mortality rate is higher, ranging between 7% 
and 34% and depends on gestational age and maternal dis-
ease severity (59, 63). 
Acute fAtty liver of pregnAncy
Acute fatty liver of pregnancy (AFLP) is an obstetric emer-
gency that, if left untreated, progresses to fulminant liver 
failure. AFLP incidence is 1 per 7,000 to 1 per 20,000 (69). 
The disease results from an autosomal recessive genetic er-
ror that causes a defect on long-chain 3-hydroxyacyl-CoA 
dehydrogenase, an enzyme involved in mitochondrial fatty 
acid beta-oxidation. There is an excessive fetal fatty acid 
accumulation to be released into the maternal circulation. 
The increased load of long-chain fatty acids is deposited 
in liver tissue and leads to impaired hepatic function in the 
mother (70). The histologic diagnosis of AFLP is based on 
the presence of lipid microvesicle infiltration of the hepato-
cytes, without inflammation or necrosis.
ALFP diagnosis depends upon clinical and laboratory 
findings. However, half of the patients have signs of pre-
eclampsia/HELLP syndrome, and at an early phase, the 
differential diagnosis may be difficult (71) (Tab. IV). Liver 
biopsy allows for definitive diagnosis. AFLP occurs in the 
third trimester of pregnancy, and the early symptoms are 
nausea, vomiting and abdominal pain. Other signs settle 
as disease progresses – for example, jaundice and hepatic 
encephalopathy (72). Women with AFLP may also present 
thrombocytopenia with or without disseminated intravas-
cular coagulation, hypoglycemia, intra-abdominal hemor-
rhage or central diabetes insipidus. Over 60% of pregnant 
women develop AKI, mostly mild and without need for di-
TABLE III 
RISK FACTORS FOR PREECLAMPSIA
Maternal obstetric factors 
Nulliparity
Multiple gestation pregnancy
History of preeclampsia 
Molar pregnancy
Obstetric paternal factors
Father born from a preeclamptic pregnancy








Factor V Leiden mutation
Preeclampsia in first-degree relative pregnancy
Other maternal factors 
Age over 40 years
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TABLE IV 




HELLP AFLP TTP aHUS
Time of diagnosis Usually 3T 3T Usually 2T/3T Postpartum
Frequency of hypertension 100% 80% 25%-50% 0/+ +
Fever / neurologic symptoms no no no yes no
Acute kidney Injury mild mild / moderate moderate mild / moderate severe
Hemolytic anemia 0 + 0/+ ++ +
Thrombocytopenia 0/+ + 0 ++ ++
Liver transaminase increase 0/+ + ++ 0 0
Partial thromboplastin time 
increase
0/+ 0/+ + 0 0
ADAMTS-13 activity <10% 0 0 0 ++ +
Recovery after delivery 2-3 days 1 week 1-2 days No recovery
Treatment Delivery; Support measures Plasma infusion /exchange
0 = absence; 0/+ = occasionally present; + = sometimes present; ++ = always present; AFLP = acute fatty liver of pregnancy; 
aHUS = atypical hemolytic uremic syndrome; HELLP = hemolysis, elevated liver enzymes and low platelet count, TTP = throm-
botic thrombocytopenic purpura; 2T = second trimester of gestation; 3T = third trimester of gestation.
alysis support (73, 74). The etiology of AKI in AFLP is mul-
tifactorial.
In most women, there is a complete liver and kidney re-
covery after delivery. However, AFLP is associated with an 
important maternal and perinatal mortality. Epidemiologic 
studies calculate a maternal and perinatal mortality between 
10% and 20% (62, 75-77).
thrombotic microAngiopAthies 
Pregnancy-associated thrombotic microangiopathies (p-
TMA) are rare, affecting 1 per 25,000 pregnancies (78). They 
are defined by the presence of fibrin and/or platelet thrombi 
in the microcirculation of multiple organs (79). Depending on 
the most affected organ (brain or kidney), 2 clinical entities 
have been described: thrombotic thrombocytopenic purpu-
ra (TTP) and HUS. TTP is characterized by fever, thrombo-
cytopenia (usually severe), microangiopathic hemolytic ane-
mia, mild renal failure (creatinine <1.4 mg/dL) and neurologic 
symptoms (disorientation, ataxia, headache, focal changes, 
seizures or aphasia) (80). HUS clinical features are similar, 
but renal involvement is more pronounced (creatinine >2.3 
mg/dL) and the presence of neurologic symptoms is rare. 
However, the clinical manifestations of these 2 entities may 
overlap, so in daily practice the distinction may be difficult. 
A disintegrin and metalloproteinase with thrombospondin mo-
tifs 13 (ADAMTS-13) is an enzyme produced by liver stellate 
cells, endothelial cells and platelets, responsible for cleaving 
ultralarge von Willebrand factor multimers (81). ADAMTS-13 
deficiency allows the circulation of this highly thrombogenic 
multimer and causes platelet aggregation and red cell frag-
mentation, and PTT ensues. This enzymatic deficiency (de-
fined by ADAMT-13 activity <10%) (82) can be congenital, as 
a result of inactivating gene mutations (rare), or acquired, by 
circulating autoantibodies (67%-83% of cases) (79, 83, 84). 
The pathogenesis of atypical HUS (i.e., non-Shiga-like-toxin-
associated HUS) is not as fully understood. It seems to be as-
sociated with a dysregulation of the alternative complement 
pathway that leads to lesions in multiple body cells, namely 
endothelial cells. Several regulatory (factor H and I, membrane 
cofactor protein [MCP,or CD46] and decay-accelerating fac-
tor [DAF] and activation factor [C3 and factorB] molecules are 
25© 2011 Società Italiana di Nefrologia - ISSN 1121-8428  
JN (2012; :01) 19- 3025EPHROL
involved in this complement pathway. Atypical HUS may then 
result from: (i) constitutional factors: inactivating mutations of 
the genes that encode the factors H, I and MCP, or activating 
gene mutations for factor B and C3; (ii) acquired factors : anti-
factor H antibodies (83, 84). ADAMTS-13 activity is normal in 
atypical HUS – a distinct aspect from PTT. Not all individuals 
with these genetic changes associated with HUS-PTT patho-
genesis will develop disease. This fact reveals the need for 
triggering factors, such as pregnancy. 
The p-TMA may occur any time during pregnancy or at puer-
perium, in previously healthy women. TTP is often diagnosed 
before delivery, especially in the second and third trimesters 
(85) because the ADAMTS-13 level physiologically tends to 
decrease during the last trimester (81, 86). Atypical HUS oc-
curs mainly in the first 6 months after delivery (87). The diag-
nosis of p-TMA is clinically challenging, due to the need to 
exclude other specific pregnancy thrombotic diseases, such 
as preeclampsia and HELLP syndrome (see Tab. IV).
The p-TMA renal involvement is common, and AKI is present 
in two thirds of cases (1). Most patients have severe renal fail-
ure requiring dialysis therapy (84). The kidney disease results 
from renal thrombotic microangiopathy and is morphologi-
cally characterized by multiple intraluminal thrombi; double 
contour appearance of capillary basement membrane; me-
sangiolysis; and arterial and arteriolar changes, including mu-
coid intimal thickening, fibrinoid necrosis or thrombosis (88).
The maternal mortality in p-TMA has declined in recent 
years and is now between 10% and 20% (1, 85). However, 
the latest epidemiologic data indicate a high perinatal mor-
tality rate (30%-80%) caused mainly by growth restriction 
and placental infarction due to thrombosis of decidua arte-
rioles (1). The long-term renal outcome is poor. Seventy-six 
percent of patients with AKI related to p-TMA develop end-
stage chronic kidney disease (84, 89).
AKi treAtment in pregnAncy
There are 3 aspects to consider in the management of AKI 
related to pregnancy: (a) renal function supportive measures, 
(b) dialysis and (c) treatment of the underlying disease. 
Renal function supportive measures 
Some important general measures to minimize renal injury 
(such as etiology treatment, suspension of nephrotoxic drugs 
or treatment of an infectious disease) should be started as 
soon as possible. The second step is administration of in-
travenous fluids to restore or maintain renal perfusion (90, 
91). This procedure also prevents hypovolemia and ensures 
an adequate uteroplacental perfusion and fetal well-being. 
These general measures are followed by pharmacologic ther-
apy of AKI and its known complications: hypertension, hy-
perkalemia, metabolic acidosis and anemia. Hypertension is 
a frequent sign in AKI related to pregnancy. There is no con-
sensus about the level at which we should start antihyper-
tensive medications (40). Some of the antihypertensive drugs 
commonly used in the general population are contraindi-
cated in pregnancy (such as angiotensin-converting enzyme 
inhibitors and angiotensin II receptor antagonists) or are not 
recommended (such as diuretics because of the high risk for 
volume depletion). Therefore the first-line treatment options 
in pregnant women are methyldopa and labetalol (92). The 
dihydropyridine calcium channel blockers can also be used 
successfully and safely in pregnancy. Hydralazine is more 
commonly used in severe hypertension (3, 93); however, its 
use has recently been associated with adverse maternal and 
fetal outcomes (94). The administration of insulin, glucose 
and ion exchange resin are recommended for the treatment 
of hyperkalemia. There are no published data about the resin 
use in pregnant women, but this drug has a local action with-
in the gastrointestinal tract, therefore, there is no reason for 
a fetal deleterious effect. In the healthy pregnant woman, a 
4 mEq/L decrease in bicarbonate concentration is common. 
This fact has to be taken into account when correcting meta-
bolic acidosis with sodium bicarbonate. Regarding anemia 
associated with AKI, blood transfusion is recommended in 
acute therapy. The erythropoiesis-stimulating agents are safe 
in pregnancy, but higher doses are usually required to obtain 
the desired therapeutic effect (95).
Dialysis
If the previous procedures prove to be insufficient, dialysis is 
the next step. The indications for dialysis are the same as for 
the general population with severe AKI: uremic symptoms 
(encephalopathy, pericarditis or neuropathy), volume over-
load, hyperkalemia and/or metabolic acidosis unresponsive 
to initial medical treatment. However, authors recommend 
starting dialysis earlier, when GFR falls to below 20 ml/min 
per 1.73 m2 (3). Any dialysis modality can be used in preg-
nancy because there are no randomized studies showing 
benefits for a specific technique. In most cases, the choice 
is intermittent hemodialysis. Some aspects must be taken 
into account when prescribing dialysis in pregnant women. 
Increasing the dialysis dose leads to an increase in fetal 
survival and prematurity decrease (96). So a daily dialysis 
program (more than 20 hours/week) (1, 95) should be es-
tablished to: (a) improve the uremic environment, a high 
risk factor for prematurity and polyhydramnios, (b) minimize 
hemodynamic fluctuations of hemodialysis that adversely 
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affect uteroplacental perfusion and increase the risk of pla-
cental oxidative stress. When establishing a dry weight, it 
is important not to forget the normal weight gain (0.3-0.5 
kg/week) in the second and third trimesters (78). Some di-
alysate parameters should be tailored in pregnant women, 
such as bicarbonate to 25 mEq/L and sodium to135 mEq/L 
(97). Heparin and low-molecular-weight heparin are safe in 
pregnancy because they do not cross the placental barrier. 
Both can be used during hemodialysis treatment (3).
Treatment of the underlying disease 
Preeclampsia/HELLP syndrome
The treatment of severe preeclampsia/HELLP syndrome 
depends on illness severity, gestational age and fetal well-
being. Figure 1 represents a proposed algorithm for preec-
lampsia management. 
Before 24 weeks of gestation, pregnancy discontinuance is 
recommended since studies show no fetal survival benefit 
and only increase the risk of severe maternal complications 
(25, 98). Between 24 and 32 weeks of gestation, the expect-
ant management is a reasonable approach (3). Delivery is 
the treatment of choice for pregnancies ≥32 weeks (25, 71, 
99). Some clinical situations are considered indications for 
prompt delivery regardless of gestational age: worsening ma-
ternal condition, eclampsia or signs of fetal compromise (3). 
Some studies show the benefit of corticosteroid therapy for 
the prognosis of HELLP syndrome. However, the results of 
the only randomized controlled trial published to date do not 
show any impact on length of hospitalization, on the speed 
of recovery or the development of complications (94).
AFLP
In AFLP, the stabilization of the maternal clinical condi-
tion through glycemic control with glucose administration 
and coagulopathy correction with fresh frozen plasma, 
blood transfusion or cryoprecipitate is essential. Hepat-
ic encephalopathy is treated with low protein diet and 
oral lactulose. Delivery should be induced immediately 
to avoid progression to liver failure. Other interventions 
may be necessary in more severe cases, including me-
chanical ventilation, parenteral nutrition, surgery or even 
liver transplantation (1, 71). Recent case reports have de-
scribed successful treatment of this condition with mo-
Fig. 1 - Proposed algorithm for the 
management of preeclampsia. AKI 
= acute kidney injury; BP = blood 
pressure; HELLP = hemolysis, el-
evated liver enzymes and low plate-
let count; MgSO4 = magnesium sul-
phate.
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lecular adsorbent recirculating systems (MARS); however, 
its practical application has yet to be validated (94).
HUS/TTP
TTP treatment includes fresh frozen plasma infusion and 
plasmapheresis (94) to correct ADAMTS-13 deficiency and 
remove the ADAMTS-13 circulating antibody. In suspected 
cases of autoimmune ADAMTS-13 deficiency, steroids are 
recommended as initial immunosuppressive therapy. Some 
published data report the use of cyclosporine and rituximab 
in patients with more serious disease (80). Response to 
therapy is best monitored by following serial serum lactate 
dehydrogenase. Treatment of atypical HUS also includes 
plasma infusion and plasma exchange to restore the miss-
ing mediators (factors H and I) and remove anti-factorH (79, 
84). Delivery does not have any influence on disease remis-
sion, but should be promptly induced if there is serious ill-
ness and/or a viable fetus. Platelet transfusions should be 
avoided if possible, because of the risk for increased micro-
vascular thrombosis.
conclusion 
The development of AKI in pregnancy is a major clinical chal-
lenge because it is necessary to consider 2 patients (mother 
and fetus) and can be caused by specific pregnancy dis-
eases not yet fully understood. It is essential to focus on 
the prevention and periodic evaluation of pregnant women 
to improve maternal and perinatal outcomes. The complex-
ity of the AKI in pregnancy requires a multidisciplinary ap-
proach where the nephrologist plays an important role. 
Financial support: This review had no financial support.
Conflict of interest statement: None declared.
Address for correspondence:
Dr. Susana Machado
Hospitais da Universidade de Coimbra




1. Gammill HS, Jeyabalan A. Acute renal failure in pregnancy. 
Crit Care Med. 2005;33(10)(Suppl):S372-S384. 
2. Rasmussen PE, Nielsen FR. Hydronephrosis during preg-
nancy: a literature survey. Eur J Obstet Gynecol Reprod Biol. 
1988;27(3):249-259. 
3. Krane NK, Hamrahian M. Pregnancy: kidney diseases and 
hypertension. Am J Kidney Dis. 2007;49(2):336-345. 
4. Danielson LA, Kercher LJ, Conrad KP. Impact of gender and 
endothelin on renal vasodilation and hyperfiltration induced 
by relaxin in conscious rats. Am J Physiol Regul Integr Comp 
Physiol. 2000;279(4):R1298-R1304.
5. Fekete A, Sasser JM, Baylis C. Chronic vasodilation pro-
duces plasma volume expansion and hemodilution in rats: 
consequences of decreased effective arterial blood volume. 
Am J Physiol Renal Physiol. 2011;300(1):F113-F118. 
6. Conrad KP, Lindheimer M. Renal and cardiovascular al-
terations. In: Lindheimer M, Roberts J, Cunningham F, eds. 
Chesley’s hypertensive disorders in pregnancy. 3rd ed. Am-
sterdam: Elsevier. 2009:297-334.
7. Jeyabalan A, Conrad KP. Renal function during normal preg-
nancy and preeclampsia. Front Biosci. 2007;12(1):2425-2437. 
8. August P. The patient with kidney disease and hyperten-
sion in pregnancy. In: Schrier RW, ed. Manual of nephrol-
ogy. 7th ed. Philadelphia, PA: Lippincott Williams & Wilkins. 
2009:220-243.
9. Zhu Y, Goff JP, Reinhardt TA, Horst RL. Pregnancy and lac-
tation increase vitamin D-dependent intestinal membrane 
calcium adenosine triphosphatase and calcium binding pro-
tein messenger ribonucleic acid expression. Endocrinology. 
1998;139(8):3520-3524. 
10. August P. The kidney in pregnancy. In: Greenberg A, Cheung 
A, Falk R, Coffman T, Jeannette J, eds. Primer on kidney dis-
eases. 4th ed. National Kidney Foundation;National Kidney 
Foundation; Philadephia, PA. 2005:426-435.
11. Piccoli GB, Conijn A, Attini R, et al. Pregnancy in chronic 
kidney disease: need for a common language. J Nephrol. 
2011;24(3):282-299. 
12. Lafayette R. AKI in pregnant patient: two lives at stake. Ne-
phrology Times. 2010;3(5):9-10.
13. Smith MC, Moran P, Ward MK, Davison JM. Assessment of 
28 © 2011 Società Italiana di Nefrologia - ISSN 1121-8428  
Machado et al: Acute kidney injury in pregnancy
glomerular filtration rate during pregnancy using the MDRD 
formula. BJOG. 2008;115(1):109-112. 
14. Alper AB, Yi Y, Webber LS, et al. Estimation of glomeru-
lar filtration rate in preeclamptic patients. Am J Perinatol. 
2007;24(10):569-574. 
15. Rodriguez-Thompson D, Lieberman ES. Use of a random 
urinary protein-to-creatinine ratio for the diagnosis of sig-
nificant proteinuria during pregnancy. Am J Obstet Gynecol. 
2001;185(4):808-811. 
16. Maynard SE, Thadhani R. Pregnancy and the kidney. J Am 
Soc Nephrol. 2009;20(1):14-22. 
17. Chan P, Brown M, Simpson JM, Davis G. Proteinuria in pre-
eclampsia: how much matters? BJOG. 2005;112(3):280-285. 
18. Martins-Costa SH, Vettorazzi J, Valério E, et al. Protein cre-
atinine ratio in random urine sample of hypertensive preg-
nant women: maternal and perinatal outcomes. Hypertens 
Pregnancy. 2011;30(3):331-337.
19. Prakash J, Niwas SS, Parekh A, et al. Acute kidney in-
jury in late pregnancy in developing countries. Ren Fail. 
2010;32(3):309-313. 
20. Dragun K, Haase M. Acute kidney failure during pregnan-
cy and postpartum. In: Jörres A, Ronco C, Kellum J, eds. 
Management of acute kidney problems. Springer; Berlin. 
2010:445-458.
21. Sibai B, Dekker G, Kupferminc M. Pre-eclampsia. Lancet. 
2005;365(9461):785-799.
22. Carty DM, Delles C, Dominiczak AF. Preeclampsia and future 
maternal health. J Hypertens. 2010;28(7):1349-1355. 
23. Forbes K, Westwood M. Maternal growth factor regulation of 
human placental development and fetal growth. J Endocri-
nol. 2010;207(1):1-16. 
24. Khankin EV, Royle C, Karumanchi SA. Placental vasculature 
in health and disease. Semin Thromb Hemost. 2010;36(3): 
309-320. 
25. Hu Y, Dutz JP, MacCalman CD, Yong P, Tan R, von Dadelszen 
P. Decidual NK cells alter in vitro first trimester extravillous 
cytotrophoblast migration: a role for IFN-γ. J Immunol. 2006; 
177(12):8522-8530.
26. Steegers EA, von Dadelszen P, Duvekot JJ, Pijnenborg R. 
Pre-eclampsia. Lancet. 2010;376(9741):631-644. 
27. Karumanchi SA, Maynard SE, Stillman IE, Epstein FH, 
Sukhatme VP. Preeclampsia: a renal perspective. Kidney Int. 
2005;67(6):2101-2113. 
28. Yagel S. Angiogenesis in gestational vascular complications. 
Thromb Res. 2011;127(Suppl 3):S64-S66. 
29. Maynard S, Epstein FH, Karumanchi SA. Preeclampsia and 
angiogenic imbalance. Annu Rev Med. 2008;59(1):61-78. 
30. Levine RJ, Maynard SE, Qian C, et al. Circulating angio-
genic factors and the risk of preeclampsia. N Engl J Med. 
2004;350(7):672-683. 
31. Silasi M, Cohen B, Karumanchi SA, Rana S. Abnormal 
placentation, angiogenic factors, and the pathogenesis of 
preeclampsia. Obstet Gynecol Clin North Am. 2010;37(2): 
239-253. 
32. Kita N, Mitsushita J. A possible placental factor for pre-
eclampsia: sFlt-1. Curr Med Chem. 2008;15(7):711-715. 
33. Venkatesha S, Toporsian M, Lam C, et al. Soluble endoglin 
contributes to the pathogenesis of preeclampsia. Nat Med. 
2006;12(6):642-649. 
34. Chen Y. Novel angiogenic factors for predicting preeclamp-
sia: sFlt-1, PIGF and soluble endoglin. Open Clinical Chem-
istry Journal. 2009;2:1-6. 
35. Foidart JM, Schaaps JP, Chantraine F, Munaut C, Lorquet S. 
Dysregulation of anti-angiogenic agents (sFlt-1, PLGF, and 
sEndoglin) in preeclampsia: a step forward but not the defini-
tive answer. J Reprod Immunol. 2009;82(2):106-111. 
36. Gupta S, Agarwal A, Sharma RK. The role of placental oxi-
dative stress and lipid peroxidation in preeclampsia. Obstet 
Gynecol Surv. 2005;60(12):807-816. 
37. Matthiesen L, Berg G, Ernerudh J, Ekerfelt C, Jonsson Y, 
Sharma S. Immunology of preeclampsia. Chem Immunol Al-
lergy. 2005;89:49-61. 
38. Redman CW, Sargent IL. Circulating microparticles in nor-
mal pregnancy and pre-eclampsia. Placenta. 2008; 29(Suppl 
A):S73-S77
39. Redman CW, Sargent IL. Pre-eclampsia, the placenta and 
the maternal systemic inflammatory response: a review. Pla-
centa 2003;24(Suppl A):S21-S27.
40. Leeman L, Fontaine P. Hypertensive disorders of pregnancy. 
Am Fam Physician. 2008;78(1):93-100.
41. Paruk F, Moodley J. Maternal and neonatal outcome in ear-
ly- and late-onset pre-eclampsia. Semin Neonatol. 2000; 
5(3):197-207. 
42. Melchiorre K, Wormald B, Leslie K, Bhide A, Thilaganathan 
B. First-trimester uterine artery Doppler indices in term 
and preterm pre-eclampsia. Ultrasound Obstet Gynecol. 
2008;32(2):133-137. 
43. Valensise H, Vasapollo B, Gagliardi G, Novelli GP. Early and 
late preeclampsia: two different maternal hemodynamic 
states in the latent phase of the disease. Hypertension. 
2008;52(5):873-880. 
44. Koopmans CM, van Pampus MG, Groen H, Aarnoudse JG, 
van den Berg PP, Mol BW. Accuracy of serum uric acid as a 
predictive test for maternal complications in pre-eclampsia: 
bivariate meta-analysis and decision analysis. Eur J Obstet 
Gynecol Reprod Biol. 2009;146(1):8-14. 
45. Karumanchi S, Epstein F. Renal complications in pregnancy. 
In: Feehally J, Floege J, Johnson R, eds. Comprehensive 
clinical nephrology. 3rd ed. Mosby; Philadelphia, PA. 2007.
46. Turner JA. Diagnosis and management of pre-eclampsia: an 
update. Int J Womens Health. 2010;2:327-337. 
47. Skjaerven R, Vatten LJ, Wilcox AJ, Rønning T, Irgens LM, Lie 
RT. Recurrence of pre-eclampsia across generations: explor-
ing fetal and maternal genetic components in a population 
based cohort. BMJ. 2005;331(7521):877. 
48. Catalano PM. Obesity, insulin resistance, and pregnancy 
outcome. Reproduction. 2010;140(3):365-371. 
49. Jacquemyn Y, Zemtsova O. Risk factors and prediction of 
29© 2011 Società Italiana di Nefrologia - ISSN 1121-8428  
JN (2012; :01) 19- 3025EPHROL
preeclampsia. Acta Clin Belg. 2010;65(1):1-12.
50. Barton JR, Sibai BM. Prediction and prevention of recur-
rent preeclampsia. Obstet Gynecol. 2008;112(2, Part 1) 
(2 Pt 1):359-372. 
51. Hofmeyr GJ, Lawrie TA, Atallah AN, Duley L. Calcium supple-
mentation during pregnancy for preventing hypertensive dis-
orders and related problems. Cochrane Database Syst Rev. 
2010;(8):CD001059.
52. Askie LM, Duley L, Henderson-Smart DJ, Stewart LA; PARIS 
Collaborative Group. Antiplatelet agents for prevention of 
pre-eclampsia: a meta-analysis of individual patient data. 
Lancet. 2007;369(9575):1791-1798. 
53. Duley L, Henderson-Smart DJ, Meher S, King JF. Antiplatelet 
agents for preventing pre-eclampsia and its complications. 
Cochrane Database Syst Rev. 2007;(2):CD004659.
54. Hauth JC, Ewell MG, Levine RJ, et al; Calcium for Pre-
eclampsia Prevention Study Group. Pregnancy outcomes in 
healthy nulliparas who developed hypertension. Obstet Gy-
necol. 2000;95(1):24-28. 
55. Bombrys AE, Barton JR, Nowacki EA, et al. Expectant man-
agement of severe preeclampsia at less than 27 weeks’ ges-
tation: maternal and perinatal outcomes according to gesta-
tional age by weeks at onset of expectant management. Am 
J Obstet Gynecol. 2008;199(3):247, e1-e6. 
56. Romundstad PR, Magnussen EB, Smith GD, Vatten LJ. Hy-
pertension in pregnancy and later cardiovascular risk: com-
mon antecedents? Circulation. 2010;122(6):579-584. 
57. Terry MB, Perrin M, Salafia CM, et al. Preeclampsia, preg-
nancy-related hypertension, and breast cancer risk. Am J 
Epidemiol. 2007;165(9):1007-1014. 
58. Strobl I, Windbichler G, Strasak A, et al. Left ventricular func-
tion many years after recovery from pre-eclampsia. BJOG. 
2011;118(1):76-83. 
59. Sibai BM. Diagnosis, controversies, and management of 
the syndrome of hemolysis, elevated liver enzymes, and low 
platelet count. Obstet Gynecol. 2004;103(5 Pt 1):981-991. 
60. Barton JR, Sibai BM. Gastrointestinal complications of pre-
eclampsia. Semin Perinatol. 2009;33(3):179-188. 
61. Pan C, Perumalswami PV. Pregnancy-related liver diseases. 
Clin Liver Dis. 2011;15(1):199-208. 
62. Joshi D, James A, Quaglia A, Westbrook RH, Heneghan MA. 
Liver disease in pregnancy. Lancet. 2010;375(9714):594-605. 
63. Picinni P, Gallo G. Diagnosis and management of HELLP 
syndrome. In: Ronco C, Bellomo R, Kellum J, eds. Criti-
cal care nephrology. 2nd ed. Saunders; Philadelphia, PA. 
2009:337-340.
64. Haram K, Svendsen E, Abildgaard U. The HELLP syndrome: 
clinical issues and management: a Review. BMC Pregnancy 
Childbirth. 2009;9(1):8. 
65. Baxter JK, Weinstein L. HELLP syndrome: the state of the 
art. Obstet Gynecol Surv. 2004;59(12):838-845. 
66. Drakeley AJ, Le Roux PA, Anthony J, Penny J. Acute renal 
failure complicating severe preeclampsia requiring admis-
sion to an obstetric intensive care unit. Am J Obstet Gynecol. 
2002;186(2):253-256. 
67. Celik C, Gezginç K, Altintepe L, et al. Results of the pregnan-
cies with HELLP syndrome. Ren Fail. 2003;25(4):613-618. 
68. Gul A, Aslan H, Cebeci A, Polat I, Ulusoy S, Ceylan Y. Mater-
nal and fetal outcomes in HELLP syndrome complicated with 
acute renal failure. Ren Fail. 2004;26(5):557-562. 
69. Knight M, Nelson-Piercy C, Kurinczuk JJ, Spark P, Brock-
lehurst P; UK Obstetric Surveillance System. A prospective 
national study of acute fatty liver of pregnancy in the UK. 
Gut. 2008;57(7):951-956. 
70. Lee NM, Brady CW. Liver disease in pregnancy. World J Gas-
troenterol. 2009;15(8):897-906. 
71. Guntupalli SR, Steingrub J. Hepatic disease and pregnancy: 
an overview of diagnosis and management. Crit Care Med. 
2005;33(10)(Suppl):S332-S339. 
72. Wei Q, Zhang L, Liu X. Clinical diagnosis and treatment of 
acute fatty liver of pregnancy: a literature review and 11 new 
cases. J Obstet Gynaecol Res. 2010;36(4):751-756. 
73. Santana L, Hernández Medina E, O’Shanahan G, Sán-
chez-Palacios M. Acute renal failure in acute fatty liver of 
pregnancy: apropos of a case. Nefrologia. 2005;25(4): 
453-454.
74. Koroshi A, Babameto A. Acute renal failure during 
acute fatty liver of pregnancy. Nephrol Dial Transplant. 
2002;17(6):1110-1112. 
75. Fesenmeier MF, Coppage KH, Lambers DS, Barton JR, Sibai 
BM. Acute fatty liver of pregnancy in 3 tertiary care centers. 
Am J Obstet Gynecol. 2005;192(5):1416-1419. 
76. Ko H, Yoshida EM. Acute fatty liver of pregnancy. Can J Gas-
troenterol. 2006;20(1):25-30.
77. Westbrook RH, Yeoman AD, Joshi D, et al. Outcomes of 
severe pregnancy-related liver disease: refining the role of 
transplantation. Am J Transplant. 2010;10(11):2520-2526. 
78. Matthews JH, Benjamin S, Gill DS, Smith NA. Pregnancy-as-
sociated thrombocytopenia: definition, incidence and natural 
history. Acta Haematol. 1990;84(1):24-29. 
79. Fakhouri F, Frémeaux-Bacchi V. Does hemolytic uremic syn-
drome differ from thrombotic thrombocytopenic purpura? 
Nat Clin Pract Nephrol. 2007;3(12):679-687. 
80. George J. The thrombotic thrombocytopenic purpura and 
hemolytic uremic syndrome: evaluation, management and 
long-term outcomes experience of the Oklahoma TTP-HUS 
registry, 1989-2007. Kidney Int. 2009;112:S52-S54.
81. Mannucci PM, Canciani MT, Forza I, Lussana F, Lattuada A, 
Rossi E. Changes in health and disease of the metallopro-
tease that cleaves von Willebrand factor. Blood. 2001;98(9): 
2730-2735. 
82. Vesely SK, George JN, Lämmle B, et al. ADAMTS13 activ-
ity in thrombotic thrombocytopenic purpura-hemolytic ure-
mic syndrome: relation to presenting features and clinical 
outcomes in a prospective cohort of 142 patients. Blood. 
2003;102(1):60-68. 
83. Besbas N, Karpman D, Landau D, et al; European Paedi-
atric Research Group for HUS. A classification of hemo-
30 © 2011 Società Italiana di Nefrologia - ISSN 1121-8428  
Machado et al: Acute kidney injury in pregnancy
lytic uremic syndrome and thrombotic thrombocytopenic 
purpura and related disorders. Kidney Int. 2006;70(3): 
423-431.
84. Fakhouri F, Roumenina L, Provot F, et al. Pregnancy-asso-
ciated hemolytic uremic syndrome revisited in the era of 
complement gene mutations. J Am Soc Nephrol. 2010;21(5): 
859-867. 
85. Martin JN Jr, Bailey AP, Rehberg JF, Owens MT, Keiser SD, 
May WL. Thrombotic thrombocytopenic purpura in 166 
pregnancies: 1955-2006. Am J Obstet Gynecol. 2008;199(2): 
98-104. 
86. George JN. The association of pregnancy with thrombotic 
thrombocytopenic purpura-hemolytic uremic syndrome. 
Curr Opin Hematol. 2003;10(5):339-344. 
87. Ruggenenti P, Cravedi P, Remuzzi G. Thrombotic microangi-
opathies including hemolytic uremic syndrome. In: Floege J, 
Johnson R, Feehally J, eds. Comprehensive clinical nephrol-
ogy. 4th ed. Mosby; Philadelphia, PA. 2010:344-355.
88. Laszik Z. Thrombotic microangiopathies. In: Silva F, D’Agati 
V, Nadasdy T, eds. Renal biopsy interpretation. Churchill Liv-
ingstone; Oklahoma. 1996.
89. Grünfeld JP, Pertuiset N. Acute renal failure in pregnancy: 
1987. Am J Kidney Dis. 1987;9(4):359-362.
90. Jeong JY, Kim SH, Lee HJ, Sim JS. Atypical low-signal-in-
tensity renal parenchyma: causes and patterns. Radiograph-
ics. 2002;22(4):833-846.
91. Brown M, Mangos G, Peek M, Plaat F. Renal disease in preg-
nancy. In: Powrin R, Greene M, Camman W, eds. De Swiet’s 
medical disorders in obstetric practice. 5th ed. Wiley-Black-
well; Oxford. 2010.
92. Vidaeff AC, Carrol MA, Rami SM. Acute hypertensive 
emergencies in pregnancy. Crit Care Med 2005;33(10 
Suppl):S307:S312
93. Souza AR, Amorim MR, Costa AA, Neto CN. Antihypertensive 
treatment in pregnancy. Acta Med Port 2010;23(1):77-84
94. Ganesan C, Maynard SE. Acute kidney injury in pregnancy: 
the thrombotic microangiopathies. J Nephrol. 2011; pii: 
DE59A637-F706-47BF-931E-A6857A01DB8A [ePub Jan14].
95. Anantharaman P, Schimdt R, Holley J. Pregnancy & renal 
diseases. In: Nissenson A, Berns J, Lerma E, eds. Current 
diagnosis and treatment: nephrology and hypertension, Mc-
Graw-Hill; International Edition. 2009:497-498.
96. Okundaye I, Abrinko P, Hou S. Registry of pregnancy in dialy-
sis patients. Am J Kidney Dis. 1998;31(5):766-773. 
97. Lindheimer M, Conrad K, Umans J. The normal and disease 
kidney in pregnancy. In: Schrier R, ed. Diseases of the kidney 
and urinary tract. Vol. 3; 8th ed. Philadelphia, PA: Lippincott 
Williams & Wilkinson; 2007:1933.
98. Magee LA, Yong PJ, Espinosa V, Côté AM, Chen I, von 
Dadelszen P. Expectant management of severe preeclamp-
sia remote from term: a structured systematic review. Hyper-
tens Pregnancy. 2009;28(3):312-347. 
99. Gaugler-Senden IP, Huijssoon AG, Visser W, Steegers EA, 
de Groot CJ. Maternal and perinatal outcome of preec-
lampsia with an onset before 24 weeks’ gestation: audit in 
a tertiary referral center. Eur J Obstet Gynecol Reprod Biol. 
2006;128(1-2):216-221. 
Accepted: July 13, 2011
